Amgen funds more of buyback in Europe
Amgen, the US biotechnology company, issued its first bonds in the European market this week, raising the equivalent of $1.48bn to help finance a $10bn share buyback programme.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts